Global /China /Healthcare /Biotechnology /3880

Medtide Inc.

3880

• SHEK: 3880 • Delayed

21.58HKD -0.8%

2.75 USD

As of 14 June 2026, Medtide Inc. has a market cap of $393.71M USD, ranking #16778 globally and #5237 in China. It ranks #1516 in the Healthcare sector, and #291 in the Biotechnology industry.

Global Rank

16778

Country Rank

5237

Sector Rank

1516

Industry Rank

291

Key Stats

Market Cap

$393.71MUSD

3.09B HKD

Enterprise Value

$245.5MUSD

1.92B HKD

Revenue (TTM)

$80.95MUSD

634.4M HKD

EBITDA (TTM)

$33.8MUSD

264.83M HKD

Net Income (TTM)

$30.86MUSD

241.89M HKD

EBITDA Margin

42%

Profit Margin

38%

PE Ratio

12.0

Forward PE

9.5

PS Ratio

4.9

PB Ratio

1.7

EV/EBITDA

7.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Qi Xu open_in_new

Employees

566

Founded

2020

Website

medtideinc.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	-1.3%	-2.9%	-22%	-29%	-28%	-24%	-24%	-24%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	3880 ISIN: CNE100006S86 Shares Out.: Shares Outstanding: 141.8M¹ Shares Float: 12.505M² TV: TradingView: HKEX: 3880 SA: Stock Analysis: HKG: 3880 YF: Yahoo Finance: 3880.HK GF: Google Finance: HKG: 3880 BA: Barron's: 3880 MS: Morningstar: XHKG: 03880	21.58 HKD	TV: TradingView: HKEX: 3880 SA: Stock Analysis: HKG: 3880 YF: Yahoo Finance: 3880.HK GF: Google Finance: HKG: 3880 BA: Barron's: 3880 MS: Morningstar: XHKG: 03880

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Medtide Inc.

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 4K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 3K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 2K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 2K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 2K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 2K%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 46K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 41K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 12K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 11K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 11K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 11K%	37.2	Switzerland

chevron_leftBack